Generated by AI
Autolus Therapeutics plc ADR is a clinical-stage biopharmaceutical company focused on developing programmed T-cell therapies for cancer and autoimmune diseases. The company applies modular cell-engineering technologies to design autologous T-cell treatments intended to recognize and eliminate diseased cells while overcoming the defenses of target tumors. Its current portfolio includes AUCATZYL, an approved therapy for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, along with multiple pipeline programs addressing hematologic malignancies, solid tumors, and autoimmune conditions. Autolus Therapeutics plc ADR plays a specialized role in the cell-therapy market, combining research, manufacturing, and commercialization capabilities in advanced immuno-oncology and next-generation gene-modified medicines.
WebsiteThe Mediaworks
London, W12 7FP
United Kingdom
The latest articles about AUTL.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Aug 3's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about AUTL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.